| Dartmouth College, A.B. | 1993 |
Dr. Brady joined Domain in 2004. Present board memberships include Asmacure, Evoke Pharma, Neuron Systems, Novadigm Therapeutics, ParinGenix, and Symphony Medical as well as observer status at Carticept Medical, Celator Pharmaceuticals, Cortria Corporation, Esperion Therapeutics, Helixis, Meritage Pharma, Microchip Biotechnologies, and Orqis Medical. In addition, he is on the grant review board for the New Jersey Commission on Science and Technology, the venture capital advisor to the New Jersey Biotechnology Council Board of Trustees, a member of the Southeast BIO Board of Directors, and an advisor to the Translational Science Institute at Wake Forest University. Prior to Domain, Dr. Brady was co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma), where he was later Executive Vice President of Strategic Development and Planning. Dr. Brady also worked as head of business development and medical director at Aderis Pharmaceuticals (acquired by Schwarz Pharma, now UCB). While at Xanthus and Aderis, Dr. Brady was a medical consultant on numerous pre-clinical programs and clinical programs in Phases I through IV. Earlier in his career, Dr. Brady was a senior associate at CB Health Ventures (now Excel Medical Ventures), a healthcare venture capital fund.
